US-based pharmaceutical bioscience company Isolagen yesterday announced commencement of the full commercialisation phase of its European autologous cellular production facility.
Headquartered in Houston, Texas in the US, Isolagen specialises in the development of autologous cellular systems (ACS) for hard and soft tissue regeneration and other therapies. Considered as a breakthrough technology in the overall approach to cosmetic and medical therapy, ACS is a process whereby a patient's own cells are extracted, reproduced through Isolagen's proprietary process, and then reintroduced to the patient for specific cosmetic and medical applications.
Isolagen says its product differs from those of other collagen development companies, as it only uses the patient's unique, living cells to produce the patient's own collagen. There is therefore no foreign substance used in this treatment protocol.
Michael Macaluso, Isolagen's CEO, stated: "This marks a key milestone in the development of Isolagen, as we have completed and opened our first full-scale, state-of-the-art facility for the manufacturing on a commercial scale of autologous cells for the treatment of cosmetic applications such as wrinkles, rhytids and acne scarring.
"We now have a facility to accommodate our anticipated volume in Europe, allowing the company to scale production efficiently as we complete the transition from a research and development entity to an earnings-focused company," he continued.
Frank DeLape, Isolagen's chairman, added: "The team is very pleased with the progress we have made in London in transitioning from the pilot laboratory to a full-scale commercial facility. Our science team, comprised of Dr Vaughan Clift and Dr Laura Licato, have proven invaluable in developing our cell expansion technology as well as the science to ensure integrity of cell viability during the shipping phase."
He also highlighted the importance of these developments as they have enabled the company to advance to allow it to service an entire continent from one laboratory, rather than requiring a facility in each country.